Identification of a 3-aminoimidazo[1,2-a]pyridine inhibitor of HIV-1 reverse transcriptase

Virology Journal

Volumn 9, Issue 1, 2012, Pages

  Elleder, Daniel ^a,d   Baiga, Thomas J ^b,e   Russell, Rebecca L ^b   Naughton, John A ^a   Hughes, Stephen H ^c   Noel, Joseph P ^b   Young, John A T ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^e EMD Millipore   (United States)

Author keywords

HIV 1; Inhibitor; NNRTI

Indexed keywords

3 AMINOIMIDAZO[1,2 A]PYRIDINE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; 3 AMINOIMIDAZO(1,2 A)PYRAZINE; 3-AMINOIMIDAZO(1,2-A)PYRAZINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IMIDAZOLE DERIVATIVE; PYRAZINE DERIVATIVE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR LIBRARY; NONHUMAN; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VIRUS REPLICATION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PHYSIOLOGY; VIROLOGY;

ANTI-HIV AGENTS; DRUG EVALUATION, PRECLINICAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; IMIDAZOLES; PYRAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SMALL MOLECULE LIBRARIES;

MLCS; MLOWN;

EID: 84870653195     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-305     Document Type: Article

References (19)

1. Zhan P, Chen X, Li D, Fang Z, De Clercq E, Liu X: HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev 2011, doi:10.1002/med.20241. Epub 2011/04/28.
2. Schreiber SL: Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000, 287:1964-1969.
3. Domling A, Ugi II: Multicomponent reactions with isocyanides. Angew Chem Int Ed Engl 2000, 39:3168-3210.
4. Dolle RE: Comprehensive survey of combinatorial library synthesis: 2004. J Comb Chem 2005, 7:739-798.
5. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46:3-26.
6. Yasri A, Berthelot D, Gijsen H, Thielemans T, Marichal P, Engels M, Hoflack J: REALISIS: a medicinal chemistry-oriented reagent selection, library design, and profiling platform. J Chem Inf Comput Sci 2004, 44:2199-2206.
7. Burke MD, Schreiber SL: A planning strategy for diversity-oriented synthesis. Angew Chem Int Ed Engl 2004, 43:46-58.
8. Connor RI, Chen BK, Choe S, Landau NR: Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206:935-944.
9. Groebke K, Weber L, Mehlin F: Synthesis of imidazo[1,2-a] annulated pyridines, pyrazines and pyrimidines by a novel three-component condensation. Synlett 1998, 6:661-663.
10. Yamashita M, Emerman M: Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J Virol 2004, 78:5670-5678.
11. Konig R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, Chiang CY, Tu BP, De Jesus PD, Lilley CE, et al: Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 2008, 135:49-60.
12. De Clercq E: The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998, 38:153-179.
13. Carroll SS, Stahlhut M, Geib J, Olsen DB: Inhibition of HIV-1 reverse transcriptase by a quinazolinone and comparison with inhibition by pyridinones. Differences in the rates of inhibitor binding and in synergistic inhibition with nucleoside analogs. J Biol Chem 1994, 269:32351-32357.
14. King RW, Klabe RM, Reid CD, Erickson-Viitanen SK: Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob Agents Chemother 2002, 46:1640-1646.
15. Morningstar ML, Roth T, Farnsworth DW, Smith MK, Watson K, Buckheit RW Jr, Das K, Zhang W, Arnold E, Julias JG, et al: Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme. J Med Chem 2007, 50:4003-4015.
16. Schindler M, Munch J, Kirchhoff F: Human immunodeficiency virus type 1 inhibits DNA damage-triggered apoptosis by a Nef-independent mechanism. J Virol 2005, 79:5489-5498.
17. Julias JG, Boyer PL, McWilliams MJ, Alvord WG, Hughes SH: Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis. Virology 2004, 322:13-21.
18. Gervaix A, West D, Leoni LM, Richman DD, Wong-Staal F, Corbeil J: A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci USA 1997, 94:4653-4658.
19. Telesnitsky A, Blain S, Goff SP: Assays for retroviral reverse transcriptase. Methods Enzymol 1995, 262:347-362.